Disease: Neoplasm, Residual ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. 16266899 2005
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE We evaluate whether molecular monitoring of minimal residual disease (MRD) using TCR delta (TCRD), TCR gamma (TCRG), and immunoglobulin H (IgH) gene rearrangements in the bone marrow (BM) is correlated with clinical events in ALL patients. 16247752 2005
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Clonal T-cell receptor gamma (TCR-gamma) rearrangements are frequently used for detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia. 16010438 2005
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. 15295608 2004
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE In conclusion, TCRB gene rearrangements occur in 35% of precursor-B-ALL patients and are relatively stable and sensitive PCR targets for detection of minimal residual disease, particularly if this concerns complete Vbeta-(Dbeta)-Jbeta rearrangements. 15470492 2004
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE By using a clone-specific CDR III probe in each patient, we were able to detect minimal residual disease (MRD) of lymphoma cells in the bone marrow and/or blood in 9 out of 14 cases (64.2%) at the onset of the disease or relapse, whereas abnormal cells in the bone marrow and/or blood were identified by routine morphological analysis in only 4 out of 22 cases (18.2%). 15240924 2004
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Junctional regions of T-cell receptor (TCR) genes provide the best tool to study clonality, lineage association and minimal residual disease (MRD) in T-ALL. 15061208 2004
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE WT1 expression was not related to either MRD detection by IgH/TCR assays or to clinical leukemic relapse. 12796792 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE These data provide insight into the immunobiological characteristics of Ig/TCR gene rearrangements in childhood precursor-B-ALL and form a useful basis for designing improved strategies for the identification and selection of MRD-PCR targets. 12970784 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Incomplete T-cell-receptor delta (TCR-delta) rearrangements are widely used for detection of minimal residual disease in childhood acute lymphoblastic leukemia. 12860036 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE We analyzed the sequences of Ig and TCR gene rearrangements obtained at presentation and relapse in 41 children with ALL to study clonal stability, which has important implications for monitoring MRD, during the course of the disease. 12946997 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Since the comparison of Ig/TCR gene rearrangements at diagnosis and relapse in our precursor-B-ALL patients did not show significant difference in the stability of different clonal PCR targets (IGH, 70%; IGK, 71%; TCRD, 67%; TCRG, 75%), we conclude that there is no 'preferential' clone-specific target for MRD monitoring. 12886245 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE A real-time PCR assay was applied for MRD quantification using LightCycler technology and the SYBR green fluorescent dye for detection of clone-specific Ig and TCR gene rearrangements as target sequences. 12384148 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. 11896540 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE We investigated whether the MRD results obtained using RT-PCR of TEL-AML1 transcripts correlated with the clinically validated genomic PCR for Ig and TCR gene rearrangements. 11841400 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The strategy used for IgH-ASO and TCR-ASO RQ-PCR assays is accurate and reliable in the clinical prospective study of MRD in childhood lymphoid malignancies. 11939263 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Clonal Ig and TCR targets for MRD detection were identified in 94 patients, with 71% of these targets being preserved at relapse. 11895762 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Until now, most PCR-based MRD studies have used semiquantitative methods for the detection of Ig and TCR gene rearrangements. 12617867 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The usage of at least two MRD-PCR targets per patient generally ensures high sensitivity (</=1:10(4) normal cells) and prevents false-negative results owing to ongoing or secondary rearrangements.MRD monitoring in childhood ALL employing Ig/TCR gene rearrangements as PCR targets has significant prognostic value. 11987915 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE A successful MRD detection approach requires a stable marker and for lymphoid leukemias clonal rearrangements of immunoglobulin (Ig) and T cell receptor (TCR) genes are commonly used. 11684274 2001
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The CDR-3 region of heavy-chain immunoglobulin has been used as a clonal marker in the study of minimal residual disease in children with acute lymphoblastic leukemia. 11723528 2001
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The chimeric status of BMT recipients was compared to minimal residual disease (MRD) detection by analysis of immunoglobulin heavy chain (IgH) and T cell receptor (TcR) genes. 10808205 2000
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The occurrence of the different types of TCRB rearrangement patterns has implications for PCR-based clonality assessment and for PCR-based detection of minimal residual disease via TCRB gene analysis. 10360387 1999
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The junctional regions of rearranged Ig/TCR genes define the specificity and sensitivity of PCR-based MRD detection in ALL and are generally used to design a patient-specific probe. 9844931 1998
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE We also evaluated whether heteroduplex analysis of polymerase chain reaction (PCR) products of rearranged Ig and TCR genes can be used for identification of molecular targets for minimal residual disease (MRD) detection. 9665194 1998